Technological advances towards extracellular vesicles mass production
| Autor: | Max Piffoux, Florence Gazeau, Alice Grangier, Claire Wilhelm, Jeanne Volatron, Amanda K. A. Silva, Julien Branchu |
|---|---|
| Přispěvatelé: | Matière et Systèmes Complexes (MSC (UMR_7057)), Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Laboratoire Physico-Chimie Curie [Institut Curie] (PCC), Institut Curie [Paris]-Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0303 health sciences
Technology [SDV]Life Sciences [q-bio] Cell Membrane Pharmaceutical Science 02 engineering and technology 021001 nanoscience & nanotechnology Extracellular vesicles 03 medical and health sciences Extracellular Vesicles Drug Delivery Systems Production (economics) Animals Humans Cell stimulation Business Biochemical engineering 0210 nano-technology ComputingMilieux_MISCELLANEOUS 030304 developmental biology |
| Zdroj: | Advanced Drug Delivery Reviews Advanced Drug Delivery Reviews, Elsevier, 2021, 176, pp.113843. ⟨10.1016/j.addr.2021.113843⟩ |
| ISSN: | 0169-409X |
| Popis: | Extracellular vesicles (EVs) are becoming essential actors in bio-therapeutics, as much for their regenerative or immunomodulatory properties as for their potential as cargo delivery vehicles. To enable the democratization of these EV-based therapies, many challenges remain such as large-scale production which is necessary to reduce costs of treatment. Herein, we review some advanced works on high-yield EV manufacturing. One approach consists in developing large-scale cell culture platforms, while others focus on cell stimulation to increase particle yield per cell. This can be done by moderate physico-chemical stresses or by disrupting cell membrane towards autoassembled vesicle-like particles. We critically compare these different techniques, keeping in mind that the field still lacks shared characterization standards, underline the importance of therapeutic potency assessment and discuss mass production strategies that have been identified in current clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect